Nouveaux Pharma products and prices in Pakistan
Importer / marketer Its products are registered under a DRAP Drug Sale Licence (DSL), typically imported finished products. Source: DRAP.
Follow price changes 🔒 Company report (Pharma Pro)Public pharmaceutical company · Karachi · Pakistan
Nouveaux Pharma Limited, formerly Novartis Pharma (Pakistan) Limited, is a Karachi-based pharmaceutical company focused on innovative and specialty therapies.
Nouveaux Pharma products in Pakistan
Nouveaux Pharma Limited has 37 medicine presentations registered in Pakistan under 16 brands, covering 14 generic medicines. Most of its products are in Oncology & immunology, Endocrine & metabolic and Hematology & thrombosis. Its brands with the most registered strengths and packs are Tasigna (Nilotinib), Sandimmun (Ciclosporin), Tegral (Carbamazepine) and Oleptiss (Deferasirox). 37 products have an official DRAP price on MedInfoBase. See all 16 brands A to Z
What is sourced, and how recent is it?
Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.
Company profile
- Company type
- Public pharmaceutical company
- Address
- 15 West Wharf Road, West Wharf, Karachi, Pakistan
- Website
- nplpk.com ↗
- Phone
- +92 21 32313386
- Corporate source details checked
- 16 Aug 2026
- Corporate profile completeness
- 88%
Company location
A sourced company location is recorded. Use the map link below for directions.
Portfolio at a glance
RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.
PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.
IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.
Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.
Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.
Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.
How complete is this profile?
Downloadable company intelligence charts
Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.
Therapeutic Portfolio Mix
Shows where the company portfolio is concentrated across broad therapeutic areas.
Portfolio distribution, not sales or market-share data.
Dosage Form Portfolio
Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.
Counts are product presentations, not production or sales volumes.
Equivalent Price Position
Shows whether safely comparable products are below, near or above the peer median unit price.
This is price-position intelligence, not sales, demand or market-share data.
Closest Portfolio Competitors
Highlights other manufacturers with the greatest generic overlap with this company portfolio.
Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.
Therapeutic areas
High-level clinical areas represented by this company’s current MedInfoBase portfolio.
Drug classes
More specific classes derived from the canonical generic and preserved curated classifications.
Dosage forms
How MedInfoBase classifies the portfolio
MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.
Deepest brand families
Unit-price positioning vs equivalent products
See where Nouveaux Pharma Limited is priced against the market
23 of its products have like-for-like competitors. Pharma Pro shows how many are priced below, near or above the market median, the company's overall price position, and product-by-product examples.
How MedInfoBase calculates price position
Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.
Portfolio overlap
Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.
🔒 3 more overlapping companies, with shared-generic detail, in Pharma Pro. Unlock
Observed database signals
These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.
Medicine portfolio
This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.
| Brand | Generic | Strength | Form | Pack | Registration | Source-listed price | Unit price | Price position |
|---|---|---|---|---|---|---|---|---|
| Afinitor | Everolimus | 5 mg | Tablet | 30's | 069519 | PKR 708,006.70 | PKR 23,600.22/tablet | 🔒 Pharma Pro |
| Afinitor | Everolimus | 10 mg | Tablet | 30's | 069520 | PKR 1,011,438.15 | PKR 33,714.61/tablet | 🔒 Pharma Pro |
| Certican | Everolimus | 0.25 mg | Tablet | 60's | 044829 | PKR 19,385.90 | PKR 323.10/tablet | 🔒 Pharma Pro |
| Certican | Everolimus | 0.75 mg | Tablet | 60's | 044830 | PKR 53,853.46 | PKR 897.56/tablet | 🔒 Pharma Pro |
| Ciloxan | Ciprofloxacin | 0.3% | Ophthalmic drops | 5 ml | 091913 | PKR 455.43 | PKR 91.09/mL | 🔒 Pharma Pro |
| Desferal | Deferoxamine mesylate (desferrioxamine) | 500 mg | Powder for solution for injection/infusion | 10's | 001958 | PKR 5,532.54 | PKR 553.25/vial/unit | No comparator |
| Exforge 10/160mg Film Coated TabletRegistry verified | Amlodipine besylate, Valsartan | — | — | — | 047571Official source ↗ | No indexed price | — | — |
| Exforge 5/160mg Film Coated TabletRegistry verified | Amlodipine besylate, Valsartan | — | — | — | 047570Official source ↗ | No indexed price | — | — |
| Exforge 5/80mg Film Coated TabletRegistry verified | Amlodipine besylate, Valsartan | — | — | — | 047569Official source ↗ | No indexed price | — | — |
| Femara | Letrozole | 2.5 mg | Tablet | 30's | 021129 | PKR 19,089.35 | PKR 636.31/tablet | 🔒 Pharma Pro |
| Glivec | Imatinib | 100 mg | Tablet | 60's | 033196 | PKR 144,571.29 | PKR 2,409.52/tablet | 🔒 Pharma Pro |
| Glivec | Imatinib | 400 mg | Tablet | 30's | 033197 | PKR 289,142.58 | PKR 9,638.09/tablet | 🔒 Pharma Pro |
| Ilevro Eye Drops (Suspension)Registry verified | Nepafenac | — | — | — | 095874Official source ↗ | No indexed price | — | — |
| KisqaliRegistry verified | Ribociclib (as succinate) ..200mg | — | — | — | 090523Official source ↗ | No indexed price | — | — |
| Mepresor | Metoprolol Tartrate | 100 mg | Tablet | 3x10 | 007823 | PKR 487.37 | PKR 16.25/tablet | 🔒 Pharma Pro |
| Nevanac Ophthalmic SuspensionRegistry verified | Nepafenac | — | — | — | 091917Official source ↗ | No indexed price | — | — |
| Oleptiss | Deferasirox | 90 mg | Tablet | 30's | 091901 | PKR 5,816.73 | PKR 193.89/tablet | No comparator |
| Oleptiss | Deferasirox | 180 mg | Tablet | 30's | 091902 | PKR 9,695.85 | PKR 323.20/tablet | 🔒 Pharma Pro |
| Oleptiss | Deferasirox | 360 mg | Tablet | 30's | 091903 | PKR 16,159.11 | PKR 538.64/tablet | 🔒 Pharma Pro |
| Revolade Tablet 50mgRegistry verified | Eltrombopag | — | — | — | 084159Official source ↗ | No indexed price | — | — |
| Sandimmun | Ciclosporin | 250 mg/5 mL (50 mg/mL) | Concentrate for solution for IV infusion | 10 x 5ml | 008008 | PKR 10,301.78 | PKR 206.04/mL | No comparator |
| Sandimmun | Ciclosporin | 100 mg/mL | Oral solution | 50 ml | 014961 | PKR 21,781.89 | PKR 435.64/mL | 🔒 Pharma Pro |
| Sandimmun | Ciclosporin | 100 mg | Capsule | 50's | 014962 | PKR 21,781.89 | PKR 435.64/capsule | 🔒 Pharma Pro |
| Sandimmun | Ciclosporin | 25 mg | Capsule | 50's | 014963 | PKR 5,446.20 | PKR 108.92/capsule | 🔒 Pharma Pro |
| Sandostatin | Octreotide | 0.1 mg | Injection | 5's | 115716 | PKR 6,809.38 | PKR 1,361.88/vial/unit | 🔒 Pharma Pro |
| Sandostatin | Octreotide | 0.05 mg | Injection | 5's | 115717 | PKR 3,415.17 | PKR 683.03/vial/unit | No comparator |
| Sandostatin LAR | Octreotide | 10 mg | Injection | 1's | 027323 | PKR 131,798.95 | PKR 131,798.95/vial/unit | No comparator |
| Sandostatin LAR | Octreotide | 20 mg | Long-acting depot injection | 1's | 027324 | PKR 171,145.26 | PKR 171,145.26/vial/unit | No comparator |
| Sandostatin LAR | Octreotide | 30 mg | Long-acting depot injection | 1's | 027325 | PKR 237,754.57 | PKR 237,754.57/vial/unit | No comparator |
| Seebri Breezhaler | Glycopyrronium | 50 mcg | Inhalation capsule | 30's | 078111 | PKR 11,177.98 | PKR 372.60/capsule | No comparator |
| Tasigna | Nilotinib | 200 mg | Capsule | 28's | 052256 | PKR 226,923.17 | PKR 8,104.40/capsule | 🔒 Pharma Pro |
| Tasigna | Nilotinib | 200 mg | Capsule | 112's | 052256 | PKR 907,692.67 | PKR 8,104.40/capsule | 🔒 Pharma Pro |
| Tasigna | Nilotinib | 150 mg | Capsule | 40's | 072543 | PKR 243,131.97 | PKR 6,078.30/capsule | 🔒 Pharma Pro |
| Tasigna | Nilotinib | 150 mg | Capsule | 112's | 072543 | PKR 680,769.50 | PKR 6,078.30/capsule | 🔒 Pharma Pro |
| Tasigna | Nilotinib | 150 mg | Capsule | 120's | 072543 | PKR 729,395.90 | PKR 6,078.30/capsule | 🔒 Pharma Pro |
| Tasigna | Nilotinib | 50 mg | Capsule | 28's | 105591 | PKR 72,754.47 | PKR 2,598.37/capsule | No comparator |
| Tasigna | Nilotinib | 50 mg | Capsule | 112's | 105591 | PKR 291,015.02 | PKR 2,598.35/capsule | No comparator |
| Tegral | Carbamazepine | 200 mg | Tablet | 50's | 021529 | PKR 540.84 | PKR 10.82/tablet | 🔒 Pharma Pro |
| Tegral | Carbamazepine | 100 mg/5 mL | Oral solution | 100 ml | 070803 | PKR 143.54 | PKR 1.44/mL | No comparator |
| Tegral | Carbamazepine | 100 mg | Tablet | 50's | 079917 | PKR 204.47 | PKR 4.09/tablet | No comparator |
| Tegral | Carbamazepine | 400 mg | Tablet | 50's | 079918 | PKR 567.96 | PKR 11.36/tablet | 🔒 Pharma Pro |
| Tobradex (Ophthalmic) OintmentRegistry verified | Dexamethasone, Tobramycin | — | — | — | 094745Official source ↗ | No indexed price | — | — |
| Tobrex | Tobramycin | 3 mg/mL | Ophthalmic drops | 5ml | 097352 | PKR 389.27 | PKR 77.85/mL | No comparator |
| Vigamox Sterile Ophthalmic SolutionRegistry verified | Moxifloxacin HCL | — | — | — | 093920Official source ↗ | No indexed price | — | — |
| Votrient Tablet 200mgRegistry verified | Pazopanib (As Hydrochloride) | — | — | — | 084161Official source ↗ | No indexed price | — | — |
| Votrient Tablet 400mgRegistry verified | Pazopanib (As Hydrochloride) | — | — | — | 084162Official source ↗ | No indexed price | — | — |
| Zometa | Zoledronic acid | 4 mg | Powder for solution for infusion | 1's | 027365 | PKR 37,956.12 | PKR 37,956.12/vial/unit | No comparator |
| Zometa | Zoledronic acid | 4 mg/100 mL | Solution for infusion | 1's | 072551 | PKR 33,275.75 | PKR 33,275.75/vial/unit | 🔒 Pharma Pro |
All 16 Nouveaux Pharma brands in Pakistan
- Afinitor Everolimus · 10 mg tablet, 5 mg tablet
- Certican Everolimus · 0.25 mg tablet, 0.75 mg tablet
- Ciloxan Ciprofloxacin · 0.3% drops
- Desferal Deferoxamine mesylate (desferrioxamine) · 500 mg infusion
- Femara Letrozole · 2.5 mg tablet
- Glivec Imatinib · 100 mg tablet, 400 mg tablet
- Mepresor Metoprolol Tartrate · 100 mg tablet
- Oleptiss Deferasirox · 180 mg tablet, 360 mg tablet, 90 mg tablet
- Sandimmun Ciclosporin · 100 mg capsule, 100 mg/mL solution, 25 mg capsule
- Sandostatin Octreotide · 0.05 mg injection, 0.1 mg injection
- Sandostatin LAR Octreotide · 10 mg injection, 20 mg injection, 30 mg injection
- Seebri Breezhaler Glycopyrronium · 50 mcg inhalation
- Tasigna Nilotinib · 150 mg capsule, 200 mg capsule, 50 mg capsule
- Tegral Carbamazepine · 100 mg tablet, 100 mg/5 mL solution, 200 mg tablet
- Tobrex Tobramycin · 3 mg/mL drops
- Zometa Zoledronic acid · 4 mg infusion, 4 mg/100 mL infusion
Nouveaux Pharma: common questions
How many products does Nouveaux Pharma have in Pakistan?
Nouveaux Pharma Limited has 37 registered medicine presentations in Pakistan, sold under 16 brands and covering 14 generic medicines.
What are the main brands of Nouveaux Pharma?
By number of registered strengths and packs, its largest brands are Tasigna (Nilotinib), Sandimmun (Ciclosporin), Tegral (Carbamazepine), Oleptiss (Deferasirox) and Sandostatin LAR (Octreotide). This is not a sales ranking.
Which therapy areas does Nouveaux Pharma cover?
The most products are in Oncology & immunology (18), Endocrine & metabolic (7), Hematology & thrombosis (4), CNS & mental health (4) and Anti-infectives (2).
Where can I see Nouveaux Pharma medicine prices?
Open any brand in the list above for its official DRAP price, pack sizes, price history and other brands of the same medicine.
MedInfoBase company-intelligence methodology
This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.
Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.
Cite this record
Manufacturer recordRecords change over time. Please cite the access date so readers can locate the version you used.